Previous 10 | Next 10 |
REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business upd...
REDWOOD CITY, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to ...
Jasper Therapeutics (NASDAQ:JSPR) has appointed veteran biopharmaceutical executive Ronald Martell as CEO, effective March 15, 2022. Prior to joining Jasper, Martell served as the President and CEO of MorphImmune. His leadership will enable Jasper to maximize the potential of its clinical sta...
REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the appointment of Ronald Martell as the company’s Chief Executive Officer effective March 15,...
Jasper Therapeutics (NASDAQ:JSPR) reported preliminary data from a phase 1b study of JSP191 to treat myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The data from 17 patients over the age of 60 with MDS or AML showed that JSP191, in combination with low dose radiation and...
JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study 17 of 17 subjects achieved successful engraftment with neutrophil recovery 12 of 15 su...
Jasper Therapeutics (JSPR +14.6%) is trading higher today on data from JSP191, a monoclonal antibody for the treatment of severe combined immunodeficiency. Results showed that the therapy led to successful engraftment, donor myeloid chimerism, and production of donor derived naïve lympho...
Gainers: Inspira Technologies (NASDAQ:IINN) +103%, Ensysce Biosciences (NASDAQ:ENSC) +53%, Jasper Therapeutics (NASDAQ:JSPR) +24%, Ambrx Biopharma (NYSE:AMAM) +17%, iSpecimen (NASDAQ:ISPC) +15%. Losers: Reata Pharmaceuticals (NASDAQ:RETA)...
JSP191 is well tolerated with no treatment-related adverse events in dose-escalation study Single-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and clinical benefit REDWOOD CITY, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Jasper T...
Jasper Therapeutics is advancing safer and more effective conditioning agents for stem cell transplantation and engineered hematopoietic stem cell therapies. The Company’s lead compound, JSP191, originally discovered by Amgen, is a targeted, humanized monoclonal antibody. T...
News, Short Squeeze, Breakout and More Instantly...
Jasper Therapeutics Inc. Company Name:
JSPR Stock Symbol:
NASDAQ Market:
Jasper Therapeutics Inc. Website:
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneou...
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CS...
2024-06-16 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...